Serono spin­off Ca­lyp­so Biotech be­comes res­i­dent at J&J's Eu­ro­pean in­cu­ba­tor, rais­es $22M+ in Se­ries A

Bank­ing on the promise of the pop­u­lar IL-15 cy­tokine, Mer­ck Serono spin­off Ca­lyp­so Biotech is the lat­est res­i­dent re­cruit to J&J’s Eu­ro­pean JLABS in­cu­ba­tor in Bel­gium. Ready to shep­herd its lead drug to­wards in-hu­man stud­ies, the Am­s­ter­dam-based start­up has al­so raised €20 mil­lion (about $22.7 mil­lion) in Se­ries A fi­nanc­ing.

The round, an­nounced on Wednes­day, was led by Gilde Health­care and Inkef Cap­i­tal, and in­clud­ed the par­tic­i­pa­tion of John­son & John­son In­no­va­tion and Ca­lyp­so’s found­ing in­vestor M Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER